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 BACKGROUND:  Diabetes mellitus (DM) increases the risk of TB recurrence. Th is study investi-
gated whether 9-month anti-TB treatment is associated with a lower risk of TB recurrence 
within 2 years aft er complete treatment than 6-month treatment in patients with DM with an 
emphasis on the impact of directly observed therapy, short course (DOTs). 
 METHODS:  Patients with pulmonary but not extrapulmonary TB receiving treatment of 173 to 
277 days between 2002 and 2010 were identifi ed from the National Health Insurance Research 
Database of Taiwan. Patients with DM were then selected and classifi ed into two groups based 
on anti-TB treatment duration (9 months vs 6 months). Factors predicting 2-year TB recur-
rence were explored using Cox regression analysis. 
 RESULTS:  Among 12,688 patients with DM and 43,195 patients without DM, the 2-year TB 
recurrence rate was 2.20% and 1.38%, respectively ( P  , .001). Of the patients with DM, recur-
rence rate decreased from 3.54% to 1.19% aft er implementation of DOTs ( P  , .001). A total of 
4,506 (35.5%) were classifi ed into 9-month anti-TB treatment group. Although a 9-month 
anti-TB treatment was associated with a lower recurrence rate (hazard ratio, 0.76 [95% CI, 
0.59-0.97]), the benefit disappeared (hazard ratio, 0.69 [95% CI, 0.43-1.11]) under DOTs. 
Other predictors of recurrence included older age, male sex, malignancy, earlier TB diagnosis 
year, culture positivity aft er 2 months of anti-TB treatment, and anti-TB treatment being 
  80% consistent with standard regimen. 
 CONCLUSIONS:  Th e 2-year TB recurrence rate is higher in a diabetic population in Taiwan and 
can be reduced by treatment supervision. Extending the anti-TB treatment by 3 months may 
also decrease the recurrence rate when treatment is not supervised. 
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 TB, a global public health threat, is still one of the 
leading causes of death among infectious diseases, espe-
cially in developing countries. 1 With the current standard 
of four combined drugs for 6 months, anti-TB treatment 
can cure most patients with TB, with a 2-year recurrence 
rate of 2% to 3%. 2,3 Th e recurrence rate can be further 
reduced by implementing the policy of directly observed 
therapy, short course (DOTs). 4 Although recurrence 
does occur, extended treatment of  . 6 months is mainly 
recommended for extrapulmonary TB, drug-resistant 
TB, or when the regimen is modifi ed because of adverse 
events, treatment failure, or nonadherence. 5 
 Th e prevalence of diabetes mellitus (DM) is increasing 
worldwide, especially in Asia, 6 where TB is also highly 
endemic. 1 Numerous studies have presented convincing 
biologic evidence supporting the causal relationship 
of DM and impaired host immunity to TB. 7-9 In Taiwan, 
DM is the most common systemic comorbidity of 
patients with TB (18.3%-22.1%). 10 In a meta-analysis, 
the relative risk of TB recurrence in patients with DM 
compared with those without DM was 3.89 (95% CI, 
2.43-6.23). 11 Given the increased recurrence rate in 
this special population, it is imperative to know whether 
increasing the duration of anti-TB treatment will reduce 
the recurrence rate, especially aft er implementation of 
DOTs. However, there is paucity of studies focusing on 
this issue, perhaps because such studies require large 
cohorts with long-term follow-up. 
 As the mandatory universal health insurance program 
off ering comprehensive medical care coverage, the 
National Health Insurance of Taiwan has covered up to 
99% of residents in Taiwan since 1996 . 12 With a longitu-
dinal follow-up of  . 22 million subjects, the National 
Health Insurance Research Database (NHIRD) provides 
suitable research material to explore the impact of med-
ical intervention on the outcome of special populations 
with long-term diseases. During the period since 2006, 
DOTs has been implemented in Taiwan. Th us, this 
study was conducted using the NHIRD to investigate 
the risk factors of TB recurrence in patients with DM, 
with special emphasis on the impact of anti-TB treatment 
duration and DOTs. 
 Materials and Methods 
 Th e institutional review board of National Taiwan University Hospital, 
Taipei, Taiwan approved this study (NTUH REC: 201112111RIC). As a 
retrospective study using an encrypted database, the institutional review 
board waived the need for informed consent. 
 Case Selection 
 Patients with pulmonary and without extrapulmonary TB diagnosed 
from 1996 to 2010 were identifi ed ( Fig 1 ). Th ose who were diagnosed 
after January 1, 2002 were selected because comprehensive data on 
mycobacteriology studies, including acid-fast smear, mycobacterial cul-
ture, identifi cation, and drug susceptibility test (DST), were available in 
NHIRD since then. Given that drug-resistant TB, especially multidrug-
resistant TB, was usually treated for  . 9 months, only patients who 
received anti-TB regimen with a duration between 173 and 277 days 
were selected. Patients were also excluded if they received any non-fi rst-
line anti-TB drugs for  . 14 days, to avoid inclusion of patients with 
drug-resistant TB or adverse reaction due to fi rst-line anti-TB drugs. 
Patients were classifi ed into two groups according to their treatment 
duration (6 vs 9 months) using 225 days as the cutoff . 
 Th e primary research outcome was TB recurrence, defi ned as recurrent 
episode of active TB within 2 years aft er completion of anti-TB treat-
ment of the fi rst episode of TB. 1 Patients were followed up for 2 years 
aft er completion of anti-TB treatment, until TB recurrence, December 
31, 2010, or withdrawal of health insurance. 
 Deﬁ nition of Active TB 
 Active pulmonary TB was defi ned by at least two ambulatory visits or 
one inpatient record with a compatible diagnosis, plus at least one pre-
scription of three or more anti-TB drugs and prescriptions of at least 
two anti-TB drugs simultaneously for   120 days within a period of 
180 days ( e-Appendix 1 ). 13 Because there was no culture result in the 
NHIRD, DST ordered aft er 2 months of anti-TB treatment was used 
as a proxy for culture positivity aft er 2 months of anti-TB treatment 
under the assumption that DST was always done for all positive culture 
aft er 2 months of treatment. 14 Anti-TB treatment was considered  . 80% 
consistent with standard regimen if isoniazid, rifamycin, ethambutol, 
and pyrazinamide were given for  . 48 days in the fi rst 2 months and 
isoniazid and rifamycin for  . 144 days in the fi rst 6 months of anti-TB 
treatment. Th e date of complete treatment was defi ned as the last date of 
simultaneous intake of two or more anti-TB drugs and without further 
anti-TB treatment in the next 60 days. Because it is diffi  cult to correctly 
determine the outcome of anti-TB treatment other than complete treat-
ment, the number of TB cases with complete anti-TB treatment within 
1 year identifi ed in the NHIRD was verifi ed with that reported from the 
Taiwan Centers for Disease Control (Taiwan CDC). 
 Deﬁ nition of DM 
 Patients were considered as having DM if they had at least one hospital 
admission or three (or more) outpatient visits with a DM diagnostic 
code ( International Classifi cation of Diseases, 9th Revision, Clinical 
Modifi cation  [ICD-9-CM] code 250 and A-code A181) within 1 year. 15 
To avoid includ ing women with gestational diabetes who returned to 
normoglycemia aft er child delivery, diabetes visit claims within 270 days 
before parturition were excluded. 16 Chronic DM complications were 
identifi ed by at least three ambulatory or inpatient visits with a compatible 
ICD-9-CM code (diabetic nephropathy 250.4; diabetic retinopathy 250.5; 
diabetic vasculopathy 250.6; diabetic neuropathy 250.7; and other dia-
betic complications 250.8 and 250.9). 
 Comorbidity and Income Status 
 Underlying comorbidities and low income were noted if they were 
present before the diagnosis of pulmonary TB according to previous 
publications ( e-Appendix 1 ). 13,17 AIDS was defined by at least two 
outpatient visits within a period of 180 days, or one inpatient record, 
or prescription of antiretroviral agents with compatible diagnoses 
(ICD-9-CM code 042-44 or V08). 
 Statistical Analysis 
 Correlation between case numbers in the NHIRD and Taiwan CDC 
were calculated by using Pearson correlation. Because of limited follow-up 
period, case numbers in 2010 were not considered in correlation analysis. 
Intergroup diff erence was calculated using independent-sample  t test 
for continuous variables and the  x - square test or Fisher exact test for 
categorical variables, as appropriate. 
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 Figure 1 – Flowchart of case selection from the National Health Insurance Research Database of Taiwan. DOTs  5 directly observed therapy, short 
course. HREZ  5 isoniazid, rifamycin, ethambutol, and pyrazinamide. 
 Cox proportional hazards regression analysis was performed to eval-
uate the impact of age, sex, year of TB diagnosis, frequency of glycated 
hemoglobin (HbA1c) check-ups, presence of any diabetic complications 
and comorbidities, income status, culture positivity after 2 months 
of treatment, duration of anti-TB treatment (9 months vs 6 months), 
anti-TB treatment being  . 80% consistent with standard regimen, and 
numbers of days covered by one or fewer anti-TB drugs in the initial 
60 days and 180 days of anti-TB treatment on the risk of TB recurrence. 
Adjusted time-to-event curves were plotted based on regression esti-
mates in the Cox model and average covariate values (average covari-
ate method). Only variables with a two-sided  P  , .05 were kept in the 
final model. All analyses were performed using the SAS, version 9.2 
(SAS Institute Inc). 
 Sensitivity Analysis 
 Sensitivity analyses were performed in three diff erent subpopulations 
( Fig 1 ), including (1) cases diagnosed in the DOTs era (2006-2010) 
(sensitivity analysis 1); (2) receiving isoniazid, rifamycin, ethambutol, 
and pyrazinamide for  . 54 days in the fi rst 2 months and isoniazid and 
rifamycin for  . 162 days in the fi rst 6 months of anti-TB treatment 
(sensitivity analysis 2); and (3) cases receiving  . 90 days of anti-DM 
medication within 365 calendar days (sensitivity analysis 3). 16 
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 Results 
 A total of 151,571 cases of pulmonary but not extrapulmo-
nary TB were identifi ed in the NHIRD between 1996 and 
2010 ( Fig 1 ). Among them, 94,777 cases were diagnosed 
between 2002 and 2010. Th e number of pulmonary TB cases 
with complete anti-TB treatment within 1 year identifi ed 
in the NHIRD has a good correlation with the number 
of all TB (Pearson correlation, 0.776) and pulmonary TB 
cases with complete treatment within 1 year (Pearson 
correlation, 0.981) reported by the Taiwan CDC ( Fig 2 ). 
 Between 2002 and 2010, 55,883 patients with pulmonary 
TB received anti-TB treatment between 6 and 9 months, 
during which the duration of any non-fi rst-line anti-TB 
drugs was   14 days ( Fig 1 ). Among them, 12,688 (22.7%) 
had concomitant DM, and the other 43,195 did not. 
Th e 2-year TB recurrence rates in the DM and non-DM 
groups were 2.20% (95% CI, 1.94%-2.45%) (279 recurrence 
cases) and 1.38% (95% CI, 0.89%-1.25%) (597 recurrence 
cases), respectively ( P  , .001 by test), both showing a 
trend of decreasing ( Fig 3 ) . Th e recurrence rate was sig-
nifi cantly higher in the DM group in 2002 to 2006 and 
in 2009 than that in the group without DM. 
 Among the 12,688 patients with DM, 5,459 (43.0%) 
were diagnosed before the implementation of DOTs and 
7,229 (57.0%) aft er. Anti-TB treatment was  . 80% consis-
tent with standard regimen in 2,089 (38.3%) of the former 
and 3,224 (44.6%) of the latter, respectively ( P  , 0.001 
by  x 2 test). Th e 2-year recurrence rate decreased from 
3.54% (95% CI, 3.21%-3.86%) (193 recurrences) in pre-
DOTs era to 1.19% (95% CI, 1.00%-1.38%) (86 recurrences) 
in the DOTs era ( P  , 0.001). 
 Th e clinical characteristics of the 12,688 cases are sum-
marized in  Table 1 . Th e mean age was 65.8   13.5 years, 
and 72.6% were men. Th e most common underlying 
comorbidity was malignancy (6.5%), followed by COPD 
(6.2%) and end-stage renal disease requiring long-term 
dialysis (2.1%). Among them, 4,506 patients (35.5%) 
were classifi ed into the 9-month anti-TB treatment 
group (257.4   15.7 days) and 8,182 (64.5%) into the 
6-month group (194.3   13.1 days). Th e distribution of 
the treatment duration is shown in  e-Figure 1 . Comparing 
with the 6-month group, patients in the 9-month group 
were younger and had a higher prevalence of any dia-
betic complication, a higher proportion of culture 
positivity aft er 2 months of anti-TB treatment, and a 
lower prevalence of malignancy and COPD. Patients in 
the 9-month group were more likely to receive HbA1c 
check-up in the fi rst 2 months and check-ups more than 
once in the fi rst 6 months. Although the mean diff erences 
were  , 2 days, numbers of days covered by one or fewer 
anti-TB drugs in the initial 60 days and 180 days of anti-TB 
treatment were signifi cantly higher in the 9-month 
group. Th e anti-TB treatment was less likely to be con-
sistent with standard regimen in the 9-month group. Th e 
2-year recurrence rate was 2.06% (95% CI, 1.82%-2.31%) 
and 2.23% (95% CI, 2.01%-2.53%) in the 9-month and 
6-month treatment groups, respectively ( P  5 .442). 
 Of the 12,688 patients with DM, multivariate Cox 
regression analysis revealed that age (adjusted hazard 
ratio [HR], 0.97 [95% CI, 0.96-0.98] for per-year 
increment), later TB diagnosis year (adjusted HR, 0.81 
[95% CI, 0.77-0.86] for per-year increment), anti-TB 
treatment being  . 80% consistent with standard 
regimen (adjusted HR, 0.72 [95% CI, 0.56-0.93]), and 
9-month anti-TB treatment (adjusted HR, 0.76 
[95% CI, 0.59-0.97]) were associated with lower risk 
for TB recurrence, whereas male sex (adjusted HR, 1.40 
[95% CI, 1.05-1.87]), malignancy (adjusted HR, 1.64 
[95% CI, 1.03-2.63]), and culture positivity after 
2-month anti-TB treatment (adjusted HR, 1.96 [95% CI, 
1.36-2.83]) were associated with higher risk ( Table 2 ) . 
 Figure 2 – Numbers of TB and PTB cases reported by the TCDC and in 
the NHIRD as well as number of DM-pulmonary patients with TB 
selected from NHIRD for further analysis in this study. DM  5 diabetes 
mellitus; NHIRD  5 National Health Insurance Research Database; 
PTB  5 pulmonary TB; TCDC  5 Taiwan Centers for Disease Control. 
 Figure 3 – Th e 2-y TB recurrence rate and its 95% CI in patients with 
and without DM receiving anti-TB treatment of pulmonary TB between 
6 and 9 mo during which the duration of non-fi rst-line anti-TB drugs 
was   14 d in the National Health Insurance Research Database of Taiwan. 
*Represents signifi cant diff erence ( P  , .05) between the two groups by  x 2 
test. See  Figure 2 legend for expansion of abbreviation. 
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 TABLE 1  ]  Clinical Characteristics at the Diagnosis of Pulmonary TB and Treatment Course of the 12,688 Patients 
With Diabetes According to the Duration of Anti-TB Treatment 
Characteristic 9 mo (n  5 4506) 6 mo (n  5 8182)  P Value
Age, y 64.4   13.9 66.5   13.3  , .001
Male 3,315 (73.6) 5,901 (72.1) .080
Year of TB diagnosis  , .001
 Pre-DOTs era (2002-2005) 2,123 (47.1) 3,336 (40.8)
 Post-DOTs era (2006-2010) 2,383 (52.9) 4,846 (59.2)
HbA1c checked in the ﬁ rst 2 mo 1,759 (39.0) 2,892 (35.3)  , .001
HbA1c check-up   2 times within 6 mo 1,370 (30.4) 2,261 (27.6) .001
Comorbidity
 Diabetic complication 2,024 (44.9) 3,493 (42.7) .015
 Malignancy 245 (5.4) 580 (7.1)  , .001
 COPD 239 (5.3) 553 (6.8) .001
 End-stage renal disease 101 (2.2) 165 (2.0) .398
 Autoimmune disease 27 (0.6) 51 (0.6) .868
 Liver cirrhosis 21 (0.5) 28 (0.3) .282
 AIDS 10 (0.2) 11 (0.1) .246
 Organ transplantation 8 (0.2) 9 (0.1) .320
 Pneumoconiosis 1 (0.0) 8 (0.1) .172
Low income 133 (3.0) 232 (2.8) .708
Duration of ATT, d 257.4   15.7 194.3   13.1  , .001
 Total d of isoniazid 208.5   77.5 160.6   56.4  , .001
 Total d of rifamycin 230.8   39.2 177.8   24.9  , .001
 Total d of ethambutol 194.5   68.8 151   50.8  , .001
 Total d of pyrazinamide 78.2   63.4 72.6   41.2  , .001
Intensive phase (initial 60 d)
 No. of d covered by isoniazid 51.7   16.6 52.9   15.7  , .001
 No. of d covered by rifamycin 53.6   9.7 54.6   8.0  , .001
 No. of d covered by ethambutol 50.6   13.5 51.3   12.8 .005
 No. of d covered by pyrazinamide 43.0   20.5 49.3   15.2  , .001
 No. of d covered by   1 drug 4.5   8.0 3.7   6.3  , .001
Initial 180 d
 No. of d covered by isoniazid 148.3   50.9 149.3   51.0 .261
 No. of d covered by rifamycin 161.7   24.3 164.7   21.3  , .001
 No. of d covered by ethambutol 142.1   44.1 141.5   45.8 .430
 No. of d covered by pyrazinamide 69.2   46.3 71.1   37.9 .020
 No. of d covered by   1 drug 13.6   15.7 11.8   13.8  , .001
80% Consistent with standard ATT a 1,607 (35.7) 3,706 (45.3)  , .001
Culture positivity after 2 mo of ATT 363 (8.1) 481 (5.9)  , .001
2-y TB recurrence rate 93 (2.1) 186 (2.3) .442
 Data presented as No. (%) or mean   SD. ATT  5 anti-TB treatment; DOTs  5 directly observed therapy, short course; HbA1c  5 glycated hemoglobin. 
 a Cases receiving isoniazid, rifamycin, ethambutol, and pyrazinamide for  . 48 d in the ﬁ rst 2 months and isoniazid and rifamycin for  . 144 d in the 
ﬁ rst 6 months of anti-TB treatment. 
Th e adjusted time-to-recurrence curves of patients 
receiving 9-month and 6-month anti-TB treatment were 
shown in  Figure 4A . 
 Among the 7,229 patients with DM with TB diagnosed 
in the DOTs era (sensitivity analysis 1), 2,383 (33.0%) 
were classifi ed into the 9-month group. Th e 2-year 
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recurrence rate was 1.01% (95% CI, 0.83%-1.18%) 
(24 recurrences) and 1.28% (95% CI, 1.08%-1.47%) 
(62 recurrences) in the 9-month and 6-month groups, 
respectively. Duration of anti-TB treatment was not an 
independent predictor of 2-year TB recurrence ( Table 3, 
 e-Table 1 ). Among the 3,184 and 10,253 cases that had a 
higher prescription consistencies with standard anti-TB 
treatment (sensitivity analysis 2) and DM medication 
(sensitivity analysis 3) ( Fig 1 ), the 2-year TB recurrence 
rate was 2.14% (95% CI, 1.88%-2.39%) and 2.34% 
(95% CI, 2.08%-2.60%), respectively. Nine-month anti-TB 
treatment was a signifi cant predictor in both sensitivity 
analyses ( e-Table 1 ,  Fig 4 ,  Table 3 ). In all sensitivity 
analyses, age was an independent factor associated with 
2-year TB recurrence (e-Table 1). 
 Discussion 
 Using the NHIRD of Taiwan, a powerful tool to investi-
gate the infl uence and long-term interactions between 
diseases and treatments, the study has three main fi ndings. 
First, there is a consistent reduction in 2-year recurrence 
rate of TB in Taiwan from 2002 to 2010. Second, com-
patible with previous reports, 11,18 the 2-year TB recur-
rence rate was higher in a diabetic population than 
that in a nondiabetic population, especially in the 
pre-DOTs era. Th ird, although 9-month anti-TB treatment 
is associated with a lower 2-year TB recurrence rate than 
6-month treatment in patients with DM, the protective 
eff ect diminishes aft er implementation of DOTs. 
 Nonadherence to anti-TB treatment due to either 
patient or health system factors, as shown by the results 
of our multivariate analysis, is the chief cause 
of recurrence and acquired drug resistance in TB. 4 By 
treatment supervision, most patient factors leading to 
nonadherence can be eliminated, resulting in reduction 
in TB recurrence. 4 Under Taiwan’s National TB Program, 
DOTs program with TB care worker engagement coun-
trywide has been provided to every smear-positive case 
since 2006. In 2007, the DOTs program was expanded 
to cover culture-positive cases and special risk groups, 
including aboriginal populations, uncooperative patients, 
and the homeless. 19 Aft er implementation of DOTs in 
Taiwan, the proportion of patients with DM whose anti-TB 
treatment was  . 80% consistent with standard regimen 
signifi cantly increased from 38.3% to 44.6%, and the 
2-year TB recurrence rate in patients with DM signifi -
cantly decreased from 3.54% to 1.19%. Along with the 
consistent reduction in TB recurrence in non-DM 
population, these fi ndings support the continuous gov-
ernment commitment in TB control and the necessity 
of continuing to implement DOTs in Taiwan. 
 Prolonging anti-TB treatment is common when 
response is suboptimal but was not recommended as a 
routine practice for patients with DM by any treatment 
guidelines, 5,20 including guidelines in Taiwan. 14 Anti-TB 
treatment is recommended to be extended for another 
3 months (for a total duration of 9 months) among patients 
with cavitary TB on initial chest radiography or in those 
with positive cultures aft er 2 months of treatment. 20 
Although a 9-month anti-TB treatment is associated 
with a lower 2-year recurrence rate in patients with DM, 
the protective eff ect waned in the post-DOTs subpopu-
lation. According to the results of our analyses, one needs 
to treat approximately 370 patients (1/[1.28%  2 1.01%]) 
for an extra 3 months to save one recurrence in the 
DOTs era. Because the retrieval of information on adverse 
events in the NHIRD is diffi  cult and unreliable, this 
study cannot judge the benefi t of reducing recurrence by 
the increased risk of adverse events and cost-eff ectiveness. 
 TABLE 2  ]  Independent Risk Factors for TB Recurrence Within 2 y After Completion of Anti-TB Treatment 
Among the 12,688 Patients With Diabetes, by Cox Proportional Hazards Regression Analysis 
Risk Factor  P Value Adjusted HR
95% CI
Lower Upper
Age, per-y increment  , .001 0.97 0.96 0.98
Sex, male vs female .022 1.40 1.05 1.87
Later TB diagnostic y, per-y increment  , .001 0.81 0.77 0.86
Malignancy, yes vs no .039 1.64 1.03 2.63
Culture positivity after 2-mo anti-TB 
treatment, yes vs no
 , .001 1.96 1.36 2.83
80% Consistency with standard anti-TB 
treatment, yes vs no
.010 0.72 0.56 0.93
Duration of anti-TB treatment, 9 mo vs 6 mo .030 0.76 0.59 0.97
 HR  5 hazard ratio. 
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 Figure 4 – A-C, Adjusted time-to-recurrence curves for diff erent anti-TB 
treatment duration were plotted based on regression estimates in the Cox 
model and average covariate values (average covariate method) in all of 
the 12,688 patients with diabetes (A), the 3,184 patients with diabetes 
with 90% consistent with standard anti-TB treatment (B), and the 
10,253 patients with diabetes receiving  . 90 days of antidiabetic medica-
tion within 365 calendar days (C). HR  5 hazard ratio. 
Until further evidence supporting an extra 3 months in 
patients with DM becomes available, implementation of 
DOTs is still the most eff ective TB control policy to pre-
vent TB recurrence. 
 Th e results of this study confi rm the fi ndings in pre-
vious reports that DM is consistently associated with 
an unfavorable outcome . 11,18,21 In patients with DM, TB 
can worsen diabetic control through infection-related 
glucose intolerance or hyperglycemia caused by interac-
tions between oral hypoglycemic drugs and anti-TB 
drugs, especially rifampicin. 22,23 Similarly, DM may 
alter the pharmacokinetics of anti-TB drugs by aff ecting 
the oral absorption and decreasing the protein binding 
of drugs and by renal insuffi  ciency or fatty liver with 
impaired drug clearance. 24 Together with a compro-
mised host immunity, suboptimal therapeutic concen-
tration of anti-TB drugs may lead to unfavorable 
outcomes, including recurrence. 
 Th e fi ndings that male sex and concomitant malig-
nancy were associated with a higher TB recurrence rate 
were consistent with the risk factors of developing 
active TB in patients with DM in Taiwan. 16 However, 
the fi nding that the risk of recurrence decreases with 
age is interesting. In a previous study using molecular 
genotyping to simultaneously detect the Beijing and 
non-Beijing strains of  Mycobacterium tuberculosis , age 
was a signifi cant predictor of multiple infections. 25 It is 
speculated that young people have higher risk of TB 
exposure due to their lifestyle and social activity. It is 
also possible that young patients with TB acquire their 
TB because of a genetic and immune predisposition, 
because the incidence of TB is usually low in young 
populations. 
 Th e present study is limited by the unavailability of 
mycobacterial study results and radiologic fi ndings. It 
is possible that anti-TB treatment was extended to 
9 months simply because of poor health condition and 
therapeutic response, such as diabetic complication and 
persistent smear positivity (confounding by indication). 
Th e presence of diabetic complication implies poorly 
controlled diabetes, which impaired host immunity 
to TB. 7-9 In addition, persistent smear positivity for 
acid-fast bacilli is an important predictor of relapse. 26 If 
this is the case, the 2-year recurrence rate of patients 
receiving longer anti-TB treatment should be higher 
than those receiving shorter treatment, thus biasing the 
results toward the null. Th is implies that the true eff ect 
of 9-month anti-TB treatment on the 2-year recurrence 
rate is likely to be larger than current estimation. 
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 TABLE 3  ]  The Impact of Duration of Anti-TB Treatment (9 mo vs 6 mo) on 2-y TB Recurrence in Sensitivity 
Analyses 
Population No. (%) of Recurrent Cases  P Value Adjusted HR
95% CI
Lower Upper
Cases diagnosed in the DOTs era (n  5 7,229) 86 (1.19) .122 0.69 0.43 1.11
Cases receiving regular anti-TB treatment a 
(n  5 3,184)
68 (2.14) .030 0.52 0.29 0.94
Cases receiving  . 90 d of DM medication 
with 1 y (n  5 10,253)
240 (2.34) .047 0.76 0.58 1.00
 DM  5 diabetes mellitus. See  Table 1 and 2 legends for expansion of other abbreviations. 
 a Cases who received isoniazid, rifamycin, ethambutol, and pyrazinamide for  . 54 d in the ﬁ rst 2 mo and isoniazid and rifamycin for  . 162 d in the 
ﬁ rst 6 mo of anti-TB treatment. 
 Acknowledgments 
 Author contributions: J.-Y. W. is guarantor of 
the paper. J.-Y. W. contributed to the draft ing 
of the manuscript; J.-Y. W. and C.-H. L. 
contributed to the approval of the manuscript; 
M.-C. L., C.-C. S., and K.-M. C. contributed 
to the review of the manuscript; C.-H. L., 
L.-N. L., and F.-Y. C. contributed to the 
revision of the manuscript; C.-C. S. and 
K.-M. C. contributed to data processing; 
J.-Y. W., C.-H. L., and L.-N. L. contributed 
to performing statistical analysis; J.-Y. W., 
M.-C. L., and C.-H. L. designed the study; 
and F.-Y. C. contributed as the director 
responsible for general organization and 
instruction . 
 Financial/nonfi nancial disclosures: Th e 
authors have reported to  CHEST that no 
potential confl icts of interest exist with 
any companies/organizations whose 
products or services may be discussed in 
this article . 
 Role of sponsors:  Th e funders had no role in 
study design, data collection and analysis, 
decision to publish, or preparation of the 
manuscript. 
 Other contributions:  We thank the National 
Health Research Institute of Taiwan for 
providing the National Health Insurance 
Research Database, and Dr Chen-Yuan Chiang 
for his critique to improve the quality of the 
paper. Details of the computer code for 
statistical analyses are available from the 
corresponding author at chlee.tw@gmail.com. 
 Additional information: Th e e-Appendix, 
e-Figure, and e-Table can be found in the 
Supplemental Materials section of the online 
article. 
 References 
  1 .  World Health Organization .  Global 
Tuberculosis Control .  Geneva, Switzerland : 
 World Health Organization ;  2011 . 
  2 .  British Th oracic Association .  A controlled 
trial of six months chemotherapy in 
pulmonary tuberculosis. Second report: 
results during the 24 months aft er the 
end of chemotherapy .  Am Rev Respir Dis . 
 1982 ; 126 ( 3 ): 460 - 462 . 
  3 .  East and Central African/British Medical 
Research Council Fift h Collaborative 
Study .  Controlled clinical trial of 4 short-
course regimens of chemotherapy 
(three 6-month and one 8-month) for 
pulmonary tuberculosis: fi nal report . 
 Tubercle .  1986 ; 67 ( 1 ): 5 - 15 .  
  4 .  Weis  SE ,  Slocum  PC ,  Blais  FX ,  et al .  Th e 
eff ect of directly observed therapy on the 
rates of drug resistance and relapse in 
tuberculosis .  N Engl J Med .  1994 ; 330 ( 17 ):
 1179 - 1184 .  
  5 .  World Health Organization .  Treatment 
of Tuberculosis: Guidelines .  4th ed. 
 Geneva, Switzerland :  World Health 
Organization ;  2009 . 
  6 .  Wild  S ,  Roglic  G ,  Green  A ,  Sicree  R , 
 King  H .  Global prevalence of diabetes: 
estimates for the year 2000 and projections 
for 2030 .  Diabetes Care .  2004 ; 27 ( 5 ):
 1047 - 1053 .  
  7 .  Martens  GW ,  Arikan  MC ,  Lee  J ,  Ren  F , 
 Greiner  D ,  Kornfeld  H .  Tuberculosis sus-
ceptibility of diabetic mice .  Am J Respir 
Cell Mol Biol .  2007 ; 37 ( 5 ): 518 - 524 .  
  8 .  Stalenhoef  JE ,  Alisjahbana  B ,  Nelwan  EJ , 
 et al .  Th e role of interferon-gamma in 
the increased tuberculosis risk in type 2 
diabetes mellitus .  Eur J Clin Microbiol 
Infect Dis .  2008 ; 27 ( 2 ): 97 - 103 .  
  9 .  Tsukaguchi  K ,  Okamura  H ,  Ikuno  M ,  et al . 
 Th e relation between diabetes mellitus 
and IFN-gamma, IL-12 and IL-10 pro-
ductions by CD4 1 alpha beta T cells and 
monocytes in patients with pulmonary 
tuberculosis [in Japanese] .  Kekkaku . 
 1997 ; 72 ( 11 ): 617 - 622 . 
  10 .  Wang  JY ,  Hsueh  PR ,  Jan  IS ,  et al .  Empirical 
treatment with a fl uoroquinolone delays 
the treatment for tuberculosis and is asso-
ciated with a poor prognosis in endemic 
areas .  Th orax .  2006 ; 61 ( 10 ): 903 - 908 .  
  11 .  Baker  MA ,  Harries  AD ,  Jeon  CY ,  et al . 
 Th e impact of diabetes on tuberculosis 
treatment outcomes: a systematic review . 
 BMC Med .  2011 ; 9 : 81 .  
  12 . Th e national health insurance statistics. 
Bureau of National Health Insurance web-
site.  http://www.nhi.gov.tw/English/
webdata/webdata.aspx?menu 5 11&menu_
id 5 296&webdata_id 5 1942&WD_ID 5 296 . 
Published 2011. Accessed September 24, 
2014. 
  13 .  Lee  CH ,  Lee  MC ,  Lin  HH ,  et al . 
 Pulmonary tuberculosis and delay in 
anti-tuberculous treatment are important 
risk factors for chronic obstructive 
Furthermore, without data on genotyping, this study 
cannot discriminate relapse due to reactivation (the primary 
concern for extending the duration of anti-TB treat-
ment) from relapse due to exogenous reinfection. 27 Th e 
reduction in TB recurrence rate may partially be 
explained by the decrease of TB incidence in Taiwan 
during the study period. 19 Th is again biased the result to 
the null and caused underestimation of protection from 
the 9-month anti-TB treatment. Th ird, the old age and 
high prevalence of comorbidities other than DM in the 
study patients limits the external generalizability of the 
study results. 
 Conclusions 
 Th ere is a consistent decline in 2-year TB recurrence 
rate from 2002 to 2010 in Taiwan. Th e recurrence rate 
in patients with DM is higher than that in patients with-
out DM and can be reduced by treatment supervision. 
Extending the anti-TB treatment by 3 months in 
patients with DM may also decrease recurrence rate 
when treatment is not supervised. 
 528  Original Research  [   1 4 7  #  2   C H E S T   F E B RUA RY   2 0 1 5   ] 
pulmonary disease .  PLoS ONE .  2012 ; 7 ( 5 ):
 e37978 .  
  14 .  Luh  KT , ed.  Taiwan Guidelines for TB 
Diagnosis and Treatment .  5th ed.  Taipei, 
Taiwan :  Centers for Disease Control, 
R.O.C. (Taiwan) ;  2013 . 
  15 .  Chang  CH SW ,  Jiang  YD ,  et al. Type 2 
diabetes prevalence and incidence 
among adults in Taiwan during 1999-2004: 
a national health insurance data set 
study.  Diabet Med.  2010 ;27(6):
636-643. 
  16 .  Lee  M-C ,  Lee  C-H ,  Shu  C-C ,  et al .  Th e 
impact of diabetes mellitus and its con-
trol on the development of tuberculosis: a 
nationwide longitudinal study in Taiwan . 
 Pharmacoepidemiol Drug Saf .  2013 ; 22 ( 9 ):
 995 - 1003 . 
  17 . Public Assistance Act. 7th ed. Taipei, 
Taiwan (R.O.C): Ministry of the Interior; 
2010. 
  18 .  Jiménez-Corona  ME ,  Cruz-Hervert  LP , 
 García-García  L ,  et al .  Association of 
diabetes and tuberculosis: impact on 
treatment and post-treatment outcomes . 
 Th orax .  2013 ; 68 ( 3 ): 214 - 220 .  
  19 . Taiwan tuberculosis control report. 
Centers for Disease Control, Department 
of Health website.  http://www.cdc.gov.
tw/uploads/fi les/201206/ccfec372-80f3-
4256-9c3a-077fb 8ccfa08.pdf . Published 
2011. Accessed September 24, 2014. 
  20 .  Blumberg  HM ,  Burman  WJ ,  Chaisson 
 RE ,  et al ;  American Th oracic Society, 
Centers for Disease Control and 
Prevention and the Infectious Diseases 
Society .  American Th oracic Society/
Centers for Disease Control and 
Prevention/Infectious Diseases Society 
of America: treatment of tubercu-
losis .  Am J Respir Crit Care Med . 
 2003 ; 167 ( 4 ): 603 - 662 .  
  21 .  Wang  CS ,  Yang  CJ ,  Chen  HC ,  et al . 
 Impact of type 2 diabetes on manifes-
tations and treatment outcome of pul-
monary tuberculosis .  Epidemiol Infect . 
 2009 ; 137 ( 2 ): 203 - 210 .  
  22 .  Niemi  M ,  Backman  JT ,  Neuvonen 
 M ,  Neuvonen  PJ ,  Kivistö  KT .  Eff ects 
of rifampin on the pharmacokinetics 
and pharmacodynamics of glyburide 
and glipizide .  Clin Pharmacol Th er . 
 2001 ; 69 ( 6 ): 400 - 406 .  
  23 .  Park  JY ,  Kim  KA ,  Kang  MH ,  Kim 
 SL ,  Shin  JG .  Eff ect of rifampin on the 
pharmacokinetics of rosiglitazone in 
healthy subjects .  Clin Pharmacol Th er . 
 2004 ; 75 ( 3 ): 157 - 162 .  
  24 .  Gwilt  PR ,  Nahhas  RR ,  Tracewell  WG . 
 Th e eff ects of diabetes mellitus on 
pharmacokinetics and pharmacody-
namics in humans .  Clin Pharmacokinet . 
 1991 ; 20 ( 6 ): 477 - 490 .  
  25 .  Wang  JY ,  Hsu  HL ,  Yu  MC ,  et al ;  TAMI 
Group .  Mixed infection with Beijing 
and non-Beijing strains in pulmonary 
tuberculosis in Taiwan: prevalence, 
risk factors, and dominant strain . 
 Clin Microbiol Infect .  2011 ; 17 ( 8 ):
 1239 - 1245 .  
  26 .  Aber  VR ,  Nunn  AJ .  Short term chemo-
therapy of tuberculosis. Factors aff ecting 
relapse following short term chemo-
therapy [in French] .  Bull Int Union 
Tuberc .  1978 ; 53 ( 4 ): 276 - 280 . 
  27 .  Wang  JY ,  Lee  LN ,  Lai  HC ,  et al .  Prediction 
of the tuberculosis reinfection propor-
tion from the local incidence .  J Infect Dis . 
 2007 ; 196 ( 2 ): 281 - 288 .  
